Rekord LOINC: 75881-3
Tylko wersja angielska ACTIVE
Szczegóły rekordu LOINC
Informacje podstawowe
| Kod LOINC: |
75881-3
FHIR
|
| Long Common Name: | Lupus anticoagulant aPTT, dRVVT and PT screening panel W Reflex |
| Short Name: | LA aPTT+dRVVT+PT W Reflex PPP |
| Status: | ACTIVE |
| Class Type: | 1 |
Fully Specified Name (FSN)
EN
Oryginalna wersja angielska
Lupus anticoagulant three screening tests W Reflex panel
:
-
:
Pt
:
PPP
:
-
:
Coag
Klasyfikacja
| Class: |
ENPANEL.COAG
|
| Consumer Name: | - |
| Order/Observation: | Order |
| Panel Type: | Panel |
Informacje dodatkowe
| Units Required: | - |
| Example Units: | - |
| UCUM Units: | - |
| Version Last Changed: | 2.67 |
Definicja i opis
EN
The lupus anticoagulant three screen panel is based primarily on the 2009 International Society of Thrombosis and Haemostasis (ISTH) and 2014 Clinical and Laboratory Standards Institute (CLSI) guidelines for detecting the presence of lupus anticoagulants (LA), with some modifications based on information from major laboratories that use three screening tests (PT, aPTT and dRVVT) as the first step in LA testing. The ISTH guidelines recommend using dRVVT as the first screening test and aPTT-LA as the second screening test, followed by reflex to mixing studies with 1:1 Pooled Normal Plasma and confirmatory testing with excess phospholipid (PL) if either of the screening tests are positive. The CLSI guidelines permit use of other screening tests in addition to aPTT and dRVVT, and also recommend changing the order of the tests to screening following by confirmatory and then mixing. Some major laboratories reflex to thrombin time (TT) and reptilase assays if any of the three screening tests have an abnormal result, so both of those tests are included in the panel. Both ISTH and CLSI recommend reporting quantitative results as the ratio of the patient result to the control result for each of the screening, mixing and confirmatory tests that are performed. However, they use different parameters for the control: ISTH recommends calculating the control based on pooled normal plasma (PNP), while CLSI recommends using the mean of the reference interval provided by the assay manufacturer. Many labs report either the actual patient result or the actual patient result and the actual/normal ratio, so we have included both options in the panel. In addition to the quantitative results, both guidelines recommend reporting a qualitative interpretation.
Powiązane nazwy
3; Anticoag; Anti-phospholipid antibody; Asympt; Asymptomatic; Clot; Clottable; COAGULATION; Coagulation assay; Coagulation inhibiting antibody; dRVVT; LA; LA 3 screen W Reflex; LAC; Lupus inhibitor; Pan; PANEL.COAGULATION; Panl; Plas; Platelet poor plasma; Pnl; Point in time; Random; Scn; Tilt tube
Struktura panelu
Ładowanie...
Ładowanie struktury panelu...